CR9923A - Compuestos triciclicos utiles como agonistas de receptores de oxitocina - Google Patents

Compuestos triciclicos utiles como agonistas de receptores de oxitocina

Info

Publication number
CR9923A
CR9923A CR9923A CR9923A CR9923A CR 9923 A CR9923 A CR 9923A CR 9923 A CR9923 A CR 9923A CR 9923 A CR9923 A CR 9923A CR 9923 A CR9923 A CR 9923A
Authority
CR
Costa Rica
Prior art keywords
oxitocine
useful
receptors agonists
triciclic
compounds
Prior art date
Application number
CR9923A
Other languages
English (en)
Inventor
Rahman Zia
Resnick Lynn
Joy Rosezweigh-Lipson Sharon
H Ring Robert
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9923A publication Critical patent/CR9923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen aqui metodos para tratar y evitar la ansiedad, trastornos relacionados con la ansiedad, esquizofrenia y trastornos relacionados con la esquizofrenia en donde dichos metodos comprenden la administracion de agonistas del receptor de oxitocina.
CR9923A 2005-10-24 2008-04-24 Compuestos triciclicos utiles como agonistas de receptores de oxitocina CR9923A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72965605P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
CR9923A true CR9923A (es) 2008-06-27

Family

ID=37834124

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9923A CR9923A (es) 2005-10-24 2008-04-24 Compuestos triciclicos utiles como agonistas de receptores de oxitocina

Country Status (15)

Country Link
US (1) US20070117794A1 (es)
EP (1) EP1948662A2 (es)
JP (1) JP2009512730A (es)
KR (1) KR20080063848A (es)
CN (1) CN101296929A (es)
AU (1) AU2006306547A1 (es)
BR (1) BRPI0617770A2 (es)
CA (1) CA2626180A1 (es)
CR (1) CR9923A (es)
EC (1) ECSP088398A (es)
GT (1) GT200800052A (es)
IL (1) IL190900A0 (es)
NO (1) NO20081835L (es)
RU (1) RU2008114374A (es)
WO (1) WO2007050353A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
CN102905720A (zh) 2010-05-18 2013-01-30 日内瓦大学 催产素样分子的新用途及相关的方法
WO2011146806A1 (en) * 2010-05-21 2011-11-24 University Of Florida Research Foundation, Inc. Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
US9585935B2 (en) * 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
DK3328864T3 (da) * 2015-07-06 2022-12-05 Kinoxis Therapeutics Pty Ltd Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
PL3551631T3 (pl) 2016-12-12 2025-03-24 Kinoxis Therapeutics Pty Ltd Agoniści receptora oksytocyny nie będący peptydem
JP7653257B2 (ja) 2018-03-23 2025-03-28 サイトー 骨格筋肥大誘発剤としてのａｌｋ５阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists

Also Published As

Publication number Publication date
BRPI0617770A2 (pt) 2011-08-09
WO2007050353A2 (en) 2007-05-03
US20070117794A1 (en) 2007-05-24
NO20081835L (no) 2008-05-20
IL190900A0 (en) 2008-11-03
WO2007050353A3 (en) 2007-06-21
CA2626180A1 (en) 2007-05-03
GT200800052A (es) 2008-10-06
ECSP088398A (es) 2008-06-30
RU2008114374A (ru) 2009-12-10
CN101296929A (zh) 2008-10-29
KR20080063848A (ko) 2008-07-07
JP2009512730A (ja) 2009-03-26
EP1948662A2 (en) 2008-07-30
AU2006306547A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
ATE469895T1 (de) Cgrp-rezeptorantagonisten
SV2010003642A (es) Compuestos
CR10872A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP088094A (es) Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a
CO6331473A2 (es) Derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetilo como antagonistas alfa2c para uso en el tratamiento de enfermedades del sistema nervioso central y periferico
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CL2013003731A1 (es) Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
DOP2006000162A (es) Nuevos anticuerpos anti-madcan
CR11621A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
NI200800260A (es) Benzoimidazole - 2 - il pirimidinas y pirazinas como moduladores del receptor de histamina h4
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
ECSP11010974A (es) Compuestos novedosos como ligandos receptores de canabinoides
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
CL2016001348A1 (es) Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
CO6470823A2 (es) Piperidinas sustituidas
EA201290558A1 (ru) Агонисты mglu2
CL2007001779A1 (es) Compuestos triciclicos, con afinidad superior por los receptores de melatonina; composicion farmaceutica; util para la profilaxis o tratamiento de la enfermedad del sueno y compuestos intermediarios.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)